FindTrial
Sign In

Lenalidomide and Dexamethasone

DRUG7 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Istituto Clinico Humanitas, University Health Network, Toronto, University Hospital, Limoges, TJ Biopharma Co., Ltd.

Conditions

Chronic Lymphocytic LeukemiaMultiple MyelomaMultiple Myeloma in RelapsePOEMS SyndromeRefractory Multiple MyelomaRenal FailureRosai-Dorfman Disease

Phase 2

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
CompletedNCT00807599
Memorial Sloan Kettering Cancer CenterMultiple Myeloma
Start: 2008-12-10End: 2018-07-31Updated: 2019-03-15
The Treatment of Lenalidomide in Patients With POEMS Syndrome
NCT00971685
Istituto Clinico HumanitasPOEMS Syndrome
Start: 2009-07-31End: 2011-07-31Target: 16Updated: 2010-09-02
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
CompletedNCT01133743
University Health Network, TorontoChronic Lymphocytic Leukemia
Start: 2010-05-31End: 2016-12-31Updated: 2017-05-03
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
CompletedNCT01270932
University Health Network, TorontoMultiple Myeloma, Renal Failure
Start: 2010-11-30End: 2017-12-18Updated: 2017-12-29
POEMS Syndrome Treatment With Lenalidomide
CompletedNCT01639898
University Hospital, LimogesPOEMS Syndrome
Start: 2012-07-01End: 2018-07-01Updated: 2026-08-31
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
NCT04924647
Peking Union Medical College HospitalRosai-Dorfman Disease
Start: 2021-06-08End: 2024-12-31Target: 16Updated: 2021-06-16

Phase 3

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
CompletedNCT03952091
TJ Biopharma Co., Ltd.Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Start: 2019-03-27End: 2024-06-30Updated: 2024-07-03

Related Papers

Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study.
2024-06-211 citations
Antibodies to watch in 2020.
2020-01-01328 citations
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
Leukemia & lymphoma/Leukemia and lymphoma2018-10-029 citations
Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions.
Journal of Clinical Oncology2018-05-20
Immunophenotypic Evidence for Reactive Polyclonal Marrow Plasmacytosis in Multiple Myeloma Patients Receiving Long-Term Lenalidomide Therapy
Blood2016-12-02
Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials
Blood2015-12-03